NASDAQ:IVA Inventiva Q2 2026 Earnings Report $3.78 +0.03 (+0.80%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$3.76 -0.01 (-0.40%) As of 09/18/2026 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Inventiva EPS ResultsActual EPSN/AConsensus EPS -$0.20Beat/MissN/AOne Year Ago EPSN/AInventiva Revenue ResultsActual RevenueN/AExpected Revenue$6.35 millionBeat/MissN/AYoY Revenue GrowthN/AInventiva Announcement DetailsQuarterQ2 2026Date9/25/2026TimeAfter Market ClosesConference Call DateMonday, September 28, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Inventiva Earnings HeadlinesInventiva (IVA) Projected to Post Quarterly Earnings on FridaySeptember 18 at 1:10 AM | americanbankingnews.comGuggenheim Sticks to Its Buy Rating for Inventiva (IVA)September 16 at 8:52 AM | theglobeandmail.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. | Banyan Hill Publishing (Ad)Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16 at 2:00 AM | seekingalpha.comInventiva To Present Lanifibranor Data Ahead Of Q4 NATiV3 ReadoutSeptember 10, 2026 | rttnews.comInventiva to Present Multiple Abstracts at Paris MASH 2026September 8, 2026 | finance.yahoo.comSee More Inventiva Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Inventiva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inventiva and other key companies, straight to your email. Email Address About InventivaInventiva (NASDAQ:IVA) S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options. Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development. Lanifibranor is not an approved medicine. Founded in 2011, Inventiva conducts its research and development activities primarily in France and works through international clinical-development programs. The company’s American depositary shares trade on the Nasdaq Capital Market under the symbol IVA, while its ordinary shares are listed on Euronext Paris.View Inventiva ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageThese 3 Stocks Are Drawing Insider Buyers for Very Different Reasons Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
